HomeCompareEQR vs HOLX

EQR vs HOLX: Dividend Comparison 2026

EQR yields 4.73% · HOLX yields 2.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $16.8K in total portfolio value
10 years
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →
HOLX
HOLX
● Live price
2.65%
Share price
$75.55
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.6K
Annual income
$314.03
Full HOLX calculator →

Portfolio growth — EQR vs HOLX

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEQRHOLX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EQR + HOLX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EQR pays
HOLX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
HOLX
Annual income on $10K today (after 15% tax)
$225.02/yr
After 10yr DRIP, annual income (after tax)
$266.93/yr
At 15% tax rate, EQR beats the other by $2,979.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EQR + HOLX for your $10,000?

EQR: 50%HOLX: 50%
100% HOLX50/50100% EQR
Portfolio after 10yr
$32.1K
Annual income
$2,066.81/yr
Blended yield
6.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on HOLX right now

EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
HOLX
Analyst Ratings
18
Buy
23
Hold
1
Sell
Consensus: Hold
Price Target
$77.80
+3.0% upside vs current
Range: $76.00 — $79.00
Altman Z
4.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EQR buys
14
HOLX buys
0
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$EQR▲ Buy$1,001 - $15,0002025-09-05
Ro Khanna🏢 House$EQR▲ Buy$1,001 - $15,0002025-08-26
Ritchie Torres🏢 House$EQR▼ Sell$1,001 - $15,0002025-07-11
Dan Newhouse🏢 House$EQR▼ Sell$1,001 - $15,0002025-04-11
Ritchie Torres🏢 House$EQR▲ Buy$1,001 - $15,0002024-09-26
Ro Khanna🏢 House$EQR▲ Buy$1,001 - $15,0002023-10-31
Daniel Goldman🏢 House$EQR▼ Sell$50,001 - $100,0002023-07-12
Dan Newhouse🏢 House$EQR▲ Buy$1,001 - $15,0002023-04-26
Ro Khanna🏢 House$EQR▲ Buy$1,001 - $15,0002023-03-24
Ro Khanna🏢 House$EQR▼ Sell$1,001 - $15,0002023-03-14
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEQRHOLX
Forward yield4.73%2.65%
Annual dividend / share$2.77$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR15.8%0%
Portfolio after 10y$40.5K$23.6K
Annual income after 10y$3,819.61$314.03
Total dividends collected$16.9K$2.9K
Payment frequencyquarterlyquarterly
SectorREITHealthcare
Analyst consensusHoldHold
Analyst price target$70.35$77.80

Year-by-year: EQR vs HOLX ($10,000, DRIP)

YearEQR PortfolioEQR Income/yrHOLX PortfolioHOLX Income/yrGap
1← crossover$11,248$547.57$10,965$264.73+$283.00EQR
2$12,701$666.53$12,004$271.27+$697.00EQR
3$14,405$814.59$13,121$277.55+$1.3KEQR
4$16,413$999.84$14,323$283.54+$2.1KEQR
5$18,795$1,232.92$15,615$289.27+$3.2KEQR
6$21,639$1,527.95$17,003$294.73+$4.6KEQR
7$25,057$1,903.80$18,493$299.93+$6.6KEQR
8$29,197$2,385.87$20,093$304.87+$9.1KEQR
9$34,250$3,008.70$21,809$309.57+$12.4KEQR
10$40,467$3,819.61$23,649$314.03+$16.8KEQR

EQR vs HOLX: Complete Analysis 2026

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →

HOLXHealthcare

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Full HOLX Calculator →
📬

Get this EQR vs HOLX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EQR vs SCHDEQR vs JEPIEQR vs OEQR vs KOEQR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.